How FDA Feedback Shapes Neuren’s NNZ-2591 Trials for Rare Brain Disorders

• FDA provided written feedback on NNZ-2591 clinical plans for HIE and Pitt Hopkins syndrome
• Additional juvenile animal data required before HIE trial initiation
• Pitt Hopkins trial design to include specific clinical global impression scale with functional outcome measure
• Neuren remains financially well-positioned to advance programs